Seroprevalence of Human Papillomavirus Types 6, 11, 16 and 18 in Chinese Women

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Ji, Jia ^a,b   Sun, Hai Kui ^a   Smith, Jennifer S ^a   Wang, He ^a   Esser, Mark T ^c,f   Hu, Shangying ^a   Pretorius, Robert G ^d   Chen, Wen ^a   Belinson, Jerome L ^e   Qiao, You Lin ^a  

^a CANCER HOSPITAL   (China)

^b OHIO STATE UNIVERSITY   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d Department of Obstetrics and Gynecology SCPMG Fontana ^*  (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f PPD Vaccines and Biologics Center of Excellence   (United States)

Author keywords

China; Human papillomavirus; Seroprevalence

Indexed keywords

EPITOPE; VIRUS ANTIBODY;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CHINA; CHINESE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOLOGY; FEMALE; HISTOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOASSAY; MAJOR CLINICAL STUDY; NONHUMAN; QUESTIONNAIRE; RURAL AREA; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUALITY; URBAN AREA; UTERINE CERVIX CARCINOMA IN SITU; VIRUS LIKE AGENT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHINA; CROSS-SECTIONAL STUDIES; FEMALE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMAN PAPILLOMAVIRUS 6; HUMANS; IMMUNOASSAY; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; QUESTIONNAIRES; RURAL POPULATION; SEROEPIDEMIOLOGIC STUDIES; SERUM; URBAN POPULATION; YOUNG ADULT;

EID: 84862317035     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-137     Document Type: Article

References (50)

1. Zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr Top Microbiol Immunol 1994, 186:131-156. 10.1007/978-3-642-78487-3_8, 8205839.
2. Schiffman MH, Brinton LA. The epidemiology of cervical carcinogenesis. Cancer 1995, 76:1888-1901. 10.1002/1097-0142(19951115)76:10+<1888::AID-CNCR2820761305>3.0.CO;2-H, 8634980.
3. Franco EL. Cancer causes revisited: human papillomavirus and cervical neoplasia. J Natl Cancer Inst 1995, 87:779-780. 10.1093/jnci/87.11.779, 7791221.
4. Swygart C. Human papillomavirus: disease and laboratory diagnosis. Br J Biomed Sci 1997, 54:299-303.
5. Schiffman MH. Recent progress in defining the epidemiology of human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 1992, 84:394-398. 10.1093/jnci/84.6.394, 1311392.
6. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Muñoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19. 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F, 10451482.
7. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, . International Agency for Research on Cancer Multicenter Cervical Cancer Study Group Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527. 10.1056/NEJMoa021641, 12571259, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group.
8. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121:621-632. 10.1002/ijc.22527, 17405118.
9. Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, Schmidt JE, Wang P, Liu YL, Li LK, Shi H, Liu JH, Xie X, Niyazi M, Yang P, Wei LH, Li LY, Li J, Liu JF, Zhou Q, Hong Y, Li L, Li Q, Zhou HL, Bian ML, Chen J, Qiao YL, Smith JS. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. Cancer Causes Control 2009, 20:1705-1713. 10.1007/s10552-009-9422-z, 19705288.
10. Workowski KA, Berman SM, . Center for Disease Control and Prevention Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006, 55:62-67. Center for Disease Control and Prevention.
11. Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv 2006, 61:S3-S14. 10.1097/01.ogx.0000221010.82943.8c, 16729902.
12. Gissmann L, Wolnik L, Ikenberg H, Koldovsky U, Schnürch HG, zur Hausen H. Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A 1983, 80:560-563. 10.1073/pnas.80.2.560, 393419, 6300854.
13. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylomata acuminate lesions from otherwise healthy and immunosuppressed patients. J Clin Microbiol 1999, 37:3316-3322. 85555, 10488198.
14. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007, 370:890-907. 10.1016/S0140-6736(07)61416-0, 17826171.
15. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, Kiviat N, Galloway DA. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 1996, 174:927-936. 10.1093/infdis/174.5.927, 8896492.
16. Castle PE, Shields T, Kirnbauer R, Manos MM, Burk RD, Glass AG, Scott DR, Sherman ME, Schiffman M. Sexual behavior, human papillomavirus type 16 (HPV 16) infection, and HPV 16 seropositivity. Sex Transm Dis 2002, 29:182-187. 10.1097/00007435-200203000-00009, 11875380.
17. Dias D, Van Doren J, Schlottmann S, Kelly S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Brown M, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 2005, 12:959-969. 1182182, 16085914.
18. Opalka D, Lachman CE, MacMullen SA, Jansen KU, Smith JF, Chirmule N, Esser MT. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 2003, 10:108-115. 145272, 12522048.
19. Belinson JL, Qiao YL, Pretorius RG, Zhang WH, Elson P, Li L, Pan QJ, Fischer C, Lorincz A, Zahniser D. Shanxi Province Cervical Cancer Screening Study: A Cross-Sectional Comparative Trial of Multiple Techniques to Detect Cervical Neoplasia. Gynecol Oncol 2001, 83:439-444. 10.1006/gyno.2001.6370, 11606114.
20. Belinson JL, Hu S, Niyazi M, Pretorius RG, Wang H, Wen C, Smith JS, Li J, Taddeo FJ, Burchette RJ, Qiao YL. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal, and vaginal self-collected specimens; implications for vaginal self-collection. Int J Cancer 2010, 127:1151-1157.
21. Belinson JL, Qiao YL, Pretorius RG, Zhang WH, Rong SD, Huang MN, Zhao FH, Wu LY, Ren SD, Huang RD, Washington MF, Pan QJ, Li L, Fife D. Shanxi Province Cervical Cancer Screening Study II: Self-Sampling for High-Risk Human Papillomavirus Compared to Direct Sampling for Human Papillomavirus and Liquid Based Cervical Cytology. Int J Gynecol Cancer 2003, 13:819-826. 10.1111/j.1525-1438.2003.13611.x, 14675319.
22. Ji J, Chang Y, Smith JS. Age-specific Prevalence of Human Papillomavirus DNA and Antibody: Systematic Review. Abstract Book, The 25th International Papillomavirus Conference Clinical & Educational Workshop 2009, 10. (P-13.16).
23. Chen CJ, Viscidi RP, Chuang CH, Huang YC, Chiu CH, Lin TY. Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: implication for optimal age of human papillomavirus vaccination. J Clin Virol 2007, 38:126-130. 10.1016/j.jcv.2006.12.004, 17210269.
24. Dondog B, Clifford GM, Vaccarella S, Waterboer T, Unurjargal D, Avirmed D, Enkhtuya S, Kommoss F, Wentzensen N, Snijders PJ, Meijer CJ, Franceschi S, Pawlita M. Human Papillomavirus Infection in Ulaanbaatar, Mongolia: A Population-Based Study. Cancer Epidemiol Biomarkers Prev 2008, 17:1731-1738. 10.1158/1055-9965.EPI-07-2796, 18628425.
25. Shin HR, Lee DH, Herrero R, Smith JS, Vaccarella S, Hong SH, Jung KY, Kim HH, Park UD, Cha HS, Park S, Touzé A, Muñoz N, Snijders PJ, Meijer CJ, Coursaget P, Franceschi S. Prevalence of human papillomavirus infection in women in Busan, South Korea. Int J Cancer 2003, 103:413-421. 10.1002/ijc.10825, 12471626.
26. Bao YP, Li N, Smith JS, Qiao YL. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS 2008, 19:106-111. 10.1258/ijsa.2007.007113, 18334063.
27. Hu S, Smith JS, Chen W, Ji J, Pretorius RG, Esser MT, Taddeo FJ, Belinson JL, Qiao YL. HPV16/18 high in precancer, low in normal cytology in China. Abstract Book, The 25th International Papillomavirus Conference Clinical & Educational Workshop 2009, 11. (P-30.20).
28. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER. Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 2009, 200:1059-1067. 10.1086/604729, 19719390.
29. Shao C, Xu W, Ye G. Sexually transmitted disease control in China (1949-1994). Chin Med Sci J 1996, 11:252-257.
30. Wang Q. Sexually transmitted diseases: incidence and distribution. Chin Med Sci J 1996, 11(1):56-62.
31. Wang H, Qiao YL. Human papillomavirus type-distribution in condylomata acuminata of mainland China: a meta-analysis. Int J STD AIDS 2008, 19:680-684. 10.1258/ijsa.2008.008040, 18824620.
32. Dillner J. The serological response to papillomaviruses. Semin Cancer Biol 1999, 9:423-430. 10.1006/scbi.1999.0146, 10712889.
33. Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, Unger ER, Reeves WC. Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 2002, 186:1396-1402. 10.1086/344354, 12404154.
34. Sukvirach S, Smith JS, Tunsakul S, Muñoz N, Kesararat V, Opasatian O, Chichareon S, Kaenploy V, Ashley R, Meijer CJ, Snijders PJ, Coursaget P, Franceschi S, Herrero R. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. J Infect Dis 2003, 187:1246-1256. 10.1086/373901, 12696004.
35. Wang SS, Schiffman M, Shields TS, Herrero R, Hildesheim A, Bratti MC, Sherman ME, Rodriguez AC, Castle PE, Morales J, Alfaro M, Wright T, Chen S, Clayman B, Burk RD, Viscidi RP. Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer 2003, 89:1248-1254. 10.1038/sj.bjc.6601272, 2394308, 14520455.
36. Matsumoto K, Yoshikawa H, Taketani Y, Yoshiike K, Kanda T. Antibodies to human papillomavirus 16, 18, 58, and 6b major capsid proteins among Japanese females. Jpn J Cancer Res 1997, 88:369-375. 10.1111/j.1349-7006.1997.tb00391.x, 9197528.
37. Chua KL, Wiklund F, Lenner P, Angström T, Hallmans G, Bergman F, Sapp M, Schiller J, Wadell G, Hjerpe A, Dillner J. A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. Int J Cancer 1996, 68:54-59. 10.1002/(SICI)1097-0215(19960927)68:1<54::AID-IJC11>3.0.CO;2-6, 8895541.
38. Shah KV, Viscidi RP, Alberg AJ, Helzlsouer KJ, Comstock GW. Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev 1997, 6:233-237.
39. Einstein MH, Studentsov YY, Ho GY, Fazzari M, Marks M, Kadish AS, Goldberg GL, Runowicz CD, Burk RD. Combined human papillomavirus DNA and human papillomavirus-like particle serologic assay to identify women at risk for high-grade cervical intraepithelial neoplasia. Int J Cancer 2007, 120:55-59. 10.1002/ijc.22176, 17036320.
40. Tachezy R, Hamsíková E, Hájek T, Mikysková I, Smahel M, Van Ranst M, Kanka J, Havránková A, Rob L, Guttner V, Slavík V, Anton M, Kratochvíl B, Kotrsová L, Vonka V. Human papillomavirus genotype spectrum in Czech women: correlation of HPV DNA presence with antibodies against HPV-16, 18, and 33 virus-like particles. J Med Virol 1999, 58:378-386. 10.1002/(SICI)1096-9071(199908)58:4<378::AID-JMV10>3.0.CO;2-P, 10421405.
41. Studentsov YY, Ho GY, Marks MA, Bierman R, Burk RD. Polymer-based enzyme-linked immunosorbent assay using human papillomavirus type 16 (HPV16) virus-like particles detects HPV16 clade-specific serologic responses. J Clin Microbiol 2003, 41:2827-2834. 10.1128/JCM.41.7.2827-2834.2003, 165285, 12843008.
42. Andersson-Ellström A, Dillner J, Hagmar B, Schiller J, Sapp M, Forssman L, Milsom I. Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 1996, 23:234-238. 10.1097/00007435-199605000-00013, 8724515.
43. Kreimer AR, Alberg AJ, Viscidi R, Gillison ML. Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis 2004, 31:247-256. 10.1097/01.OLQ.0000118425.49522.2C, 15028941.
44. Wideroff L, Schiffman MH, Hoover R, Tarone RE, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, Lorincz AT, Manos MM, Glass AG, Scott DR, Sherman ME, Buckland J, Lowy D, Schiller J. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. J Infect Dis 1996, 174:937-943. 10.1093/infdis/174.5.937, 8896493.
45. Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 1997, 4:122-126. 170489, 9067643.
46. Dillner J, Kallings I, Brihmer C, Sikström B, Koskela P, Lehtinen M, Schiller JT, Sapp M, Mårdh PA. Seropositivities to human papillomavirus types 16, 18, or 33 capsids and to Chlamydia trachomatis are markers of sexual behavior. J Infect Dis 1996, 173:1394-1398. 10.1093/infdis/173.6.1394, 8648211.
47. Olsen AO, Dillner J, Gjøen K, Magnus P. Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med 1997, 73:131-135. 1195789, 9215097.
48. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 2000, 181:1911-1919. 10.1086/315498, 10837170.
49. Syrjänen S, Waterboer T, Sarkola M, Michael K, Rintala M, Syrjanen K, Grenman S, Pawlita M. Dynamics of human papillomavirus serology in women followed up for 36 months after pregnancy. J Gen Virol 2009, 90:1515-1526. 10.1099/vir.0.007823-0, 19264653.
50. Konya J, Dillner J. Immunity to oncogenic human papillomaviruses. Adv Cancer Res 2001, 82:205-238.